Evidence map›Paper›PMID 36532031›Full record

Trial reportFrontiers in immunology2022

Impact of exposure to malaria and nutritional status on responses to the experimental malaria vaccine ChAd63 MVA ME-TRAP in 5-17 month-old children in Burkina Faso.

Richard Morter, Alfred B Tiono, Issa Nébié, Oliver Hague, Alphonse Ouedraogo, Amidou Diarra, Nicola K Viebig, Adrian V S Hill, Katie J Ewer, Sodiomon B Sirima

Registry-linked trialOpen access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01635647 (A Phase 1/2b Double Blind Randomised Controlled Trial of the Efficacy, Safety and Immunogenicity of Heterologous Prime-boost Immunisation With the Candidate Malaria Vaccines ChAd63 ME-TRAP and MVA ME-TRAP in 5-17 Month Old Burkinabe Infants and Children), which is not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01635647 phase1 / phase2completednot on this map

A Phase 1/2b Double Blind Randomised Controlled Trial of the Efficacy, Safety and Immunogenicity of Heterologous Prime-boost Immunisation With the Candidate Malaria Vaccines ChAd63 ME-TRAP and MVA ME-TRAP in 5-17 Month Old Burkinabe Infants and Children

TypeinterventionalSponsorUniversity of OxfordRan2012 to 2014Enrolled730ConditionsMalariaArmsChAd63 ME-TRAP and MVA ME-TRAP, Rabies vaccine
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Review
  5. Review
  6. Frontiers in immunology · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 3 countries.

Richard MorterNuffield Department of Clinical Medicine, The Jenner Institute, University of Oxford, Oxford, United Kingdom.
Alfred B TionoCentre National de Recherche et de Formation sur le Paludisme, Ouagadougou, Burkina Faso.
Issa NébiéGroupe de Recherche Action en Santé (GRAS), Ouagadougou, Burkina Faso.
Oliver HagueNuffield Department of Clinical Medicine, The Jenner Institute, University of Oxford, Oxford, United Kingdom.
Alphonse OuedraogoGroupe de Recherche Action en Santé (GRAS), Ouagadougou, Burkina Faso.
Amidou DiarraGroupe de Recherche Action en Santé (GRAS), Ouagadougou, Burkina Faso.
Nicola K ViebigEuropean Vaccine Initiative, UniversitätsKlinikum Heidelberg, Heidelberg, Germany.
Adrian V S HillNuffield Department of Clinical Medicine, The Jenner Institute, University of Oxford, Oxford, United Kingdom.
Katie J EwerNuffield Department of Clinical Medicine, The Jenner Institute, University of Oxford, Oxford, United Kingdom.
Sodiomon B SirimaGroupe de Recherche Action en Santé (GRAS), Ouagadougou, Burkina Faso.
Groupe de Recherche et d’Action sur le Foncier · BFJenner Institute · GBUniversity of Oxford · GBCentre National de Recherche et de Formation sur le Paludisme · BFVienna Vaccine Safety Initiative · DE

Funding

Medical Research CouncilWellcome Trust 109026/Z/15/Z
6 · The paper itself

Abstract

The experimental malaria vaccine ChAd63 MVA ME-TRAP previously showed protective efficacy against Trial Registration: Pactr.org, identifier PACTR201208000404131; ClinicalTrials.gov, identifier NCT01635647.

Indexed as

MalariaMalaria VaccinesAdenoviruses, SimianAdultBurkina FasoChildHumansImmunoglobulin GInfantKenyaVaccinia virusImmunoglobulin GMalaria VaccinesBurkina FasoimmunosuppressionmalariaME-TRAPnutritionvaccineviral vector

Identifiers

PMID36532031
PMCPMC9755991
OpenAlexW4311111728

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.